Hope Tribune

Peritoneal Cancer Pipeline Report builds Understanding of the Limitations and Challenges with Regard to the Development | Major Companies – Pfizer, AbbVie, and Others

 Breaking News
  • No posts were found

Peritoneal Cancer Pipeline Report builds Understanding of the Limitations and Challenges with Regard to the Development | Major Companies – Pfizer, AbbVie, and Others

April 26
20:00 2023
Peritoneal Cancer Pipeline Report builds Understanding of the Limitations and Challenges with Regard to the Development | Major Companies - Pfizer, AbbVie, and Others

DelveInsight’s, “Peritoneal Cancer Pipeline Insight 2023” report provides comprehensive insights about 55+ companies and 55+ pipeline drugs in Peritoneal Cancer pipeline landscape. It covers the Peritoneal Cancer pipeline drug profiles, including Peritoneal Cancer clinical trials and nonclinical stage products. It also covers the Peritoneal Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from Peritoneal Cancer Pipeline Report

 

  • DelveInsight’s Peritoneal Cancer pipeline report depicts a robust space with 55+ active players working to develop 55+ pipeline therapies for Peritoneal Cancer treatment.

 

  • The leading Peritoneal Cancer Companies include ImmunoVaccine Technologies, Inc. (IMV Inc.), ImmunoGen, Merck & Co, Pfizer, Novartis Pharmaceuticals, Imunon, Pfizer, AbbVie, Astex Pharmaceuticals Inc, and others

 

  • Promising Peritoneal Cancer Pipeline Therapies include Nemvaleukin, olvimulogene nanivacirepvec, ZEN003694, 131 I-8H9, Dostarlimab, STRO-002, ZN-c3,  CDX-1140, TRK-950, RP12146, SL-172154, Galinpepimut S,AVB-001, MEK162, BP1001-A, Mirvetuximab Soravtansine, sodium selenite pentahydrate, Oregovomab, Trabectedin, Navicixizumab, Pembrolizumab, DCVAC/OvCa, DPX-Survivac, Adavosertib, Gimatecan, GEN-1, DSP-7888, Relacorilant, Topotecan, PF-06873600, Enzalutamide, REGN5668, Bevacizumab, Onapristone, Durvalumab, SG001, tisotumab vedotin, Guadecitabine, ATX-101, ART0380, and others

 

  • The Peritoneal Cancer companies and academics are working to assess challenges and seek opportunities that could influence Peritoneal Cancer R&D. The Peritoneal Cancer therapies under development are focused on novel approaches to treat/improve Peritoneal Cancer.

 

Request a sample and discover the recent breakthroughs happening in the Peritoneal Cancer Pipeline landscape @ Peritoneal Cancer Pipeline Outlook Report

 

Peritoneal Cancer Overview

The peritoneum is a membrane that covers the inner lining of the abdominal cavity and the organs lying in there. It helps to support these organs and contains the blood vessels and nerves that supply them. The space in the abdominal cavity covered by the peritoneum is known as the peritoneal cavity. Peritoneal metastases refer to cancer that has spread to the peritoneum from other organs.

 

Recent Developmental Activities in the Peritoneal Cancer Treatment Landscape

 

  • Enlivex has planned to initiate a Phase Ib trial evaluating Allocetra in combination with chemotherapy in solid peritoneal tumors in Q3 2022. The company evaluated preclinical studies in peritoneal cancer that shown a substantial survival benefit when Allocetra is combined with chimeric antigen receptor (CAR) T-cell therapy.

 

  • In January 2022, Avenge Bio, announced the closing of its Series A financing of $45 Million. The round of financing was co-led by Perceptive Xontogeny Venture Fund and CAM Capital, with participation from seed investor Longitude Capital and new investors Rock Springs Capital and Pappas Capital. Proceeds from the Series A financing will be used to advance Avenge Bio’s lead program, AVB-001, through the filing of an Investigational New Drug (IND) application and into the clinic for the treatment of metastatic peritoneal cancers, with a primary focus on recurrent and refractory ovarian cancer.

 

  • GRN-300 (previously ARN3261) is an orally bioavailable first-in-class novel, small molecule, dual inhibitor of the salt-inducible kinases 2 and 3 (SIK2, SIK3). A Phase I os being conducted to evaluate the safety, pharmacokinetics and efficacy of GRN-300 alone and in combination with paclitaxel, in recurrent ovarian, primary peritoneal, and fallopian tube cancers.

 

  • In August 2021, the FDA granted a fast track designation to STRO-002 for use in patients with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have previously received 1 to 3 lines of systemic therapy.

 

  • In December 2021, Ascentage Pharma entered into a clinical collaboration with Clover Biopharmaceuticals, to evaluate Ascentage Pharma’s APG-1387, a second mitochondria-derived activator of caspase (SMAC)-mimetic/inhibitor of apoptosis proteins (IAP) antagonist, in combination with Clover’s SCB-313, a recombinant human TRAIL-trimer fusion protein, in a Phase Ib/II study in patients with advanced peritoneal carcinomatosis.

 

For further information, refer to the detailed Peritoneal Cancer Drugs Launch, Peritoneal Cancer Developmental Activities, and Peritoneal Cancer News, click here for Peritoneal Cancer Ongoing Clinical Trial Analysis

 

Peritoneal Cancer Emerging Drugs Profile

 

  • Mirvetuximab soravtansine: ImmunoGen

Mirvetuximab soravtansine (IMGN853) is a first-in-class ADC comprising a folate receptor alpha (FRα)-binding antibody, cleavable linker, and the maytansinoid payload DM4, a potent tubulin-targeting agent to kill the targeted cancer cells. The drug is being studied in phase III stage of development for the treatment of patients with Peritoneal Cancer.

 

  • Pembrolizumab: Merck & Co

Pembrolizumab is a highly selective humanized monoclonal IgG4 antibody directed against the PD-1 receptor on the cell surface. The drug blocks the PD-1 receptor, preventing binding and activation of PD-L1 and PD-L2. This mechanism causes the activation of T-cell mediated immune responses against tumor cells. Pembrolizumab is a medication used in the management and treatment of various oncologic conditions. It is in the cancer immunotherapy class of drugs. Currently it is being evaluated in Phase III stage of development for the treatment of Peritoneal Cancer.

 

  • PF-06873600: Pfizer

PF-06873600 selectively targets, binds to and inhibits the activity of CDKs. Inhibition of these kinases leads to cell cycle arrest, induction of apoptosis and inhibition of tumor cell proliferation. The drug is being investigated in Phase II stage of development for the treatment of Peritoneal Cancer, HR+ HER2- Metastatic Breast Cancer, Ovarian Cancer, and Fallopian Tube Cancer.

 

Peritoneal Cancer Pipeline Therapeutics Assessment

There are approx. 55+ key companies which are developing the therapies for Peritoneal Cancer. The companies which have their Peritoneal Cancer drug candidates in the most advanced stage, i.e. Phase III include, ImmunoGen.

 

Find out more about the Peritoneal Cancer Pipeline Segmentation, Therapeutics Assessment, and Peritoneal Cancer Emerging Drugs @ Peritoneal Cancer Treatment Landscape

 

Scope of the Peritoneal Cancer Pipeline Report

 

  • Coverage- Global

 

  • Peritoneal Cancer Companies- ImmunoVaccine Technologies, Inc. (IMV Inc.), ImmunoGen, Merck & Co, Pfizer, Novartis Pharmaceuticals, Imunon, Pfizer, AbbVie, Astex Pharmaceuticals Inc, and others

 

  • Peritoneal Cancer Pipeline Therapies- Nemvaleukin, olvimulogene nanivacirepvec, ZEN003694, 131 I-8H9, Dostarlimab, STRO-002, ZN-c3,  CDX-1140, TRK-950, RP12146, SL-172154, Galinpepimut S,AVB-001, MEK162, BP1001-A, Mirvetuximab Soravtansine, sodium selenite pentahydrate, Oregovomab, Trabectedin, Navicixizumab, Pembrolizumab, DCVAC/OvCa, DPX-Survivac, Adavosertib, Gimatecan, GEN-1, DSP-7888, Relacorilant, Topotecan, PF-06873600, Enzalutamide, REGN5668, Bevacizumab, Onapristone, Durvalumab, SG001, tisotumab vedotin, Guadecitabine, ATX-101, ART0380, and others .

 

  • Peritoneal Cancer Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

 

Dive deep into rich insights for drugs for Peritoneal Cancer Pipeline Companies and Therapies, click here @ Peritoneal Cancer Unmet Needs and Analyst Views

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Peritoneal cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Late Stage Products (Phase III)
  7. Mirvetuximab soravtansine: ImmunoGen
  8. Drug profiles in the detailed report…..
  9. Mid Stage Products (Phase II)
  10. PF-06873600: Pfizer
  11. Drug profiles in the detailed report…..
  12. Early stage products (Phase I/II)
  13. ART0380: Artios Pharma
  14. Drug profiles in the detailed report…..
  15. Inactive Products
  16. Peritoneal cancer Key Companies
  17. Peritoneal cancer Key Products
  18. Peritoneal cancer- Unmet Needs
  19. Peritoneal cancer- Market Drivers and Barriers
  20. Peritoneal cancer- Future Perspectives and Conclusion
  21. Peritoneal cancer Analyst Views
  22. Peritoneal cancer Key Companies
  23. 23.   Appendix

 

Got Queries? Find out the related information on peritoneal cancer Mergers and acquisitions, peritoneal cancer Licensing Activities @ Peritoneal cancer Recent Trends, and Future Perspectives

 

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Categories